InflaRx N.V. (NASDAQ:IFRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the eight analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $7.3333.
IFRX has been the subject of a number of analyst reports. HC Wainwright increased their price objective on shares of InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Zacks Research cut shares of InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Cantor Fitzgerald increased their price target on InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Raymond James Financial upgraded InflaRx from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $7.00 to $9.00 in a research report on Wednesday, May 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday, June 24th.
View Our Latest Stock Report on InflaRx
InflaRx Trading Down 1.8%
InflaRx (NASDAQ:IFRX – Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). As a group, equities analysts predict that InflaRx will post -0.31 earnings per share for the current year.
Institutional Investors Weigh In On InflaRx
A number of hedge funds have recently bought and sold shares of IFRX. Sanctuary Advisors LLC bought a new position in shares of InflaRx during the 2nd quarter valued at approximately $25,000. AXQ Capital LP bought a new stake in InflaRx in the second quarter worth $41,000. Cubist Systematic Strategies LLC boosted its stake in InflaRx by 33.9% during the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares during the period. HRT Financial LP bought a new position in InflaRx during the fourth quarter valued at $47,000. Finally, Concurrent Investment Advisors LLC increased its position in InflaRx by 56.9% during the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after acquiring an additional 19,200 shares during the last quarter. Hedge funds and other institutional investors own 42.39% of the company’s stock.
InflaRx Company Profile
InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.
Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.
See Also
- Five stocks we like better than InflaRx
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
